Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gallamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 16/20 | 0.56 |
| ▸ | CHRNB4 | P30926 | 12/20 | 0.56 |
| ▸ | CHRNA3 | P32297 | 12/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 9/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 9/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gallamine SCHEMBL249090 | 0.98 | CHRM2 (1.00) | CHRM2ALOX15LMNACHRM1TSHR | |
| SCHEMBL19300483 | 0.95 | CHRM2 (0.90) | CHRM2ALOX15LMNACHRM1TSHR | |
| Gallamine SCHEMBL1736255 | 0.93 | CHRM2 (0.87) | CHRM2ALOX15LMNACHRM1TSHR | |
| SCHEMBL16884476 | 0.87 | CHRM2 (0.77) | CHRM2ALOX15LMNACHRM1TSHR | |
| SCHEMBL8557526 | 0.77 | LMNA (0.62) | CHRM2ALOX15LMNACHRM1TSHR | |
| SCHEMBL3265285 | 0.77 | CHRM2 (0.59) | CHRM2ALOX15LMNACHRM1TSHR | |
| SCHEMBL1238407 | 0.75 | LMNA (0.60) | CHRM2ALOX15LMNACHRM1TSHR | |
| SCHEMBL13658189 | 0.73 | LMNA (0.58) | CHRM2ALOX15LMNACHRM1TSHR | |
| SCHEMBL13385235 | 0.72 | CHRNA7 (1.00) | ALOX15CHRNA7CHRNB4CHRNA3CHRNB2 | |
| SCHEMBL456438 | 0.72 | CHRM2 (0.56) | CHRM2ALOX15LMNACHRM1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| CN-118613258-A | Esters of 8-methyl-8-azabicyclo [3.2.1] oct-3-yl 3-hydroxy-2-phenylpropionate | ADS医疗有限责任公司 | 2024-09-06 | — | — | CN | disclosed |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | TUFTS MEDICAL CENTER (US) | 2024-08-13 | — | — | US | disclosed |
| CN-108699013-B | Spiroquinone derivative, method for preparing the same, and pharmaceutical composition for preventing or treating neurological disorders containing the same as an active ingredient | 嘉泉大学校校产学协力团 | 2022-05-06 | — | — | CN | disclosed |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
| CN-114341343-A | Alpha-synuclein assay | 才思治疗公司 | 2022-04-12 | — | — | CN | disclosed |
| US-10233219-B2 | Methods and systems for designing and/or characterizing soluble lipidated ligand agents | TUFTS MEDICAL CENTER (US) | 2019-03-19 | — | — | US | disclosed |
| US-9956229-B2 | Acyclic cucurbit[n]uril type molecular containers to treat intoxication and decrease relapse rate in substance abuse disorders | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170246180-A1 | ACYCLIC CUCURBIT[N]URIL TYPE MOLECULAR CONTAINERS TO TREAT INTOXICATION AND DECREASE RELAPSE RATE IN SUBSTANCE ABUSE DISORDERS | GENERAL HOSPITAL CORPORATION | 2017-08-31 | — | — | US | disclosed |
| US-9469648-B2 | Reversal of drug-induced neuromuscular block using novel molecular containers | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2016-10-18 | — | — | US | disclosed |
| WO-2016061571-A1 | ACYCLIC CUCURBIT(N)URIL TYPE MOLECULAR CONTAINERS TO TREAT INTOXICATION AND DECREASE RELAPSE RATE IN SUBSTANCE ABUSE DISORDERS | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2016-04-21 | — | — | WO | disclosed |
| US-20160052982-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2016-02-25 | — | — | US | disclosed |
| WO-2013074059-A2 | CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2013-05-23 | — | — | WO | disclosed |
| US-20130071786-A1 | COATING COMPOSITION AND IMAGE-FORMING MATERIAL, LITHOGRAPHIC PRINTING PLATE PRECURSOR AND OXYGEN-BLOCKING FILM INCLUDING THE COATING COMPOSITION | FUJIFILM CORPORATION (JP) | 2013-03-21 | — | — | US | disclosed |
| US-20130071786-A1 | COATING COMPOSITION AND IMAGE-FORMING MATERIAL, LITHOGRAPHIC PRINTING PLATE PRECURSOR AND OXYGEN-BLOCKING FILM INCLUDING THE COATING COMPOSITION | FUJIFILM CORPORATION (JP) | 2013-03-21 | — | — | US | disclosed |
| US-7947854-B2 | Phospholipase inhibitor; prevention or therapy of microbial infection; bactericides; fungicides; viricides; parasiticides; using quaternary or phosphonium group containing compounds | THE UNIVERSITY OF SYDNEY (AU) | 2011-05-24 | — | — | US | disclosed |
| EP-2045662-A2 | Lithographic printing plate precursor and method of preparing lithographic printing plate | FUJIFILM Corporation (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-20080275003-A1 | Bis-Cationic Compounds and Use Thereof | THE UNIVERSITY OF SYDNEY (AU) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | CHRM2 2169/4885ALOX15 743/4885LMNA 2571/4885 |
| US-20080275003-A1 | Bis-Cationic Compounds and Use Thereof | PLCB1, PLCB3, PLA2G4B | CHRM2 3986/4885ALOX15 656/4885LMNA 841/4885 |
| US-20170246180-A1 | ACYCLIC CUCURBIT[N]URIL TYPE MOLECULAR CONTAINERS TO TREAT INTOXICATION AND DECREASE RELAPSE RATE IN SUBSTANCE ABUSE DISORDERS | CNR1, CNR2, OPRM1 | CHRM2 1069/4885ALOX15 3066/4885LMNA 3286/4885 |
| US-20160052982-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | CHRM2 2169/4885ALOX15 743/4885LMNA 2571/4885 |
| US-10233219-B2 | Methods and systems for designing and/or characterizing soluble lipidated ligand agents | LDLR, HDLBP, LIPG | CHRM2 2169/4885ALOX15 743/4885LMNA 2571/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | CHRM2 2169/4885ALOX15 743/4885LMNA 2571/4885 |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | LIPG, CD40, LDLR | CHRM2 1928/4885ALOX15 223/4885LMNA 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.